Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H16O6 |
Molecular Weight | 388.3695 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(C=CC=C2)C(CC3=C4C=CC=CC4=CC(C(O)=O)=C3O)=C1O
InChI
InChIKey=WLJNZVDCPSBLRP-UHFFFAOYSA-N
InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)
Molecular Formula | C23H16O6 |
Molecular Weight | 388.3695 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20826425Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Pamoic acid, also called embonic acid, is a naphthoic acid derivative, used as a counter ion of a drug compound to increase the solubility of the drug in water. Pamoic acid has agonist activity for the orphan G protein-coupled receptor GPR35 by which it activates ERK and beta-arrestin2, and causes antinociceptive activity. Although (like other drug salts) it has been considered an inactive compound by the FDA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1293267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
79.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. | 2001 |
|
Pharmacokinetic disposition and faecal excretion of pyrantel embonate following oral administration in horses. | 2001 Feb |
|
Resistance against migrating ascaris suum larvae in pigs immunized with infective eggs or adult worm antigens. | 2001 Jun |
|
Vitamin B12 and folic acid in children with intestinal parasitic infection. | 2002 Apr |
|
Ziprasidone and migraine headache. | 2002 Aug |
|
Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. | 2002 Jul 15 |
|
Serum mineral levels in children with intestinal parasitic infection. | 2003 |
|
Anthelmintic treatment in horses: the extra-label use of products and the danger of under-dosing. | 2003 Jun |
|
Population-S benzimidazole- and tetrahydropyrimidine-resistant small strongyles in a pony herd in Kentucky (1977-1999): effects of anthelmintic treatment on the parasites as determined in critical tests. | 2003 Nov |
|
Appendiceal enterobius vermicularis infestation associated with right-sided chronic pelvic pain. | 2004 Apr-Jun |
|
Studies on the development of taste-masked suspension of chloroquine. | 2004 Dec |
|
Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. | 2004 Feb |
|
Presence of immunoglobulins and antigens in serum, lung and small intestine in Ascaris suum infected and immunised pigs. | 2004 Jan 5 |
|
Adverse drug reactions to anthelmintics. | 2004 Mar |
|
Common intestinal parasites. | 2004 Mar 1 |
|
Management of biliary ascariasis in pregnancy. | 2005 Oct |
|
Target animal safety and tolerance study of pyrantel pamoate paste (19.13% w/w pyrantel base) administered orally to horses. | 2005 Winter |
|
Cyathostomes in horses in Canada resistant to pyrantel salts and effectively removed by moxidectin. | 2006 Aug 31 |
|
Pinning down pinworms. | 2006 May |
|
Field evaluation of the efficacy and the safety of a combination of oxantel/pyrantel/praziquantel in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestations in dogs in Europe. | 2007 Apr 10 |
|
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. | 2008 |
|
Anthelmintic prescribing patterns of a sample of general practitioners from selected areas in the colombo district of sri lanka. | 2008 Apr |
|
Structural insights on the pamoic acid and the 8 kDa domain of DNA polymerase beta complex: towards the design of higher-affinity inhibitors. | 2008 Apr 16 |
|
The little-known scenario of anthelmintic resistance in equine cyathostomes in Italy. | 2008 Dec |
|
Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. | 2008 Mar 26 |
|
Gateways to clinical trials. | 2008 Oct |
|
Influence of Bi 58 Nowy (38% dimethoate) on pyrantel embonate concentration in the liver of rats. | 2009 |
|
Olanzapine pamoate - blockbuster or damp squib? | 2009 Apr |
|
Fixed drug eruption resulting from fluconazole use: a case report. | 2009 Jul 6 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Abdominal Constriction Test in Mice were used for Pamoic acid activity evaluation. Four groups of 10 male, Swiss-Webster mice (30–35 g; Ace Animals, Inc., Boyertown, PA) were used. They were then injected with saline or one of three doses of pamoic acid disodium (25, 50, and 100 mg/kg s.c.). Twenty minutes later, each mouse was challenged with 0.6% acetic acid (0.30 ml/30 g animal i.p.) and, after an additional 5 min, was observed over the subsequent 10 min for abdominal writhing behavior.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
U2OS cells transiently expressing human GPR35b and _arr2-GFP or HEK 293 cells transiently expressing mouse GPR35 and beta arr2-GFP were used 48 h after transfection. U2OS cells permanently expressing HA-GPR35a and _arr2-GFP (UGPR35_) were used for most experiments. Cells were plated onto coverslips, placed in 24-well plates, and pretreated for 1 h with 0.02 mg/ml poly-Dlysine. Cells were maintained at 37°C in 5% CO2 until ready for experiments (80–85% confluent) and washed once with HBSS before drug application and experiments were performed in HBSS. Agonist stimulated redistribution of _arr2-GFP was assessed after drug treatment for 40 min. Experiments involving antagonist were done with 15 min preincubation of antagonist for both the stable UGPR35 cells and the transiently transfected mouse GPR35 HEK293 cells. To examine reversibility of the antagonist, cells were preincubated with 100 nM CID2745687 for 10 min, then washed with HBSS five times for 5 min each before adding 1 mkM pamoic acid. Cells were then fixed with 4% paraformaldehyde for 20 min at room temperature followed by three washes with HBSS.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 11:00:06 UTC 2023
by
admin
on
Thu Jul 06 11:00:06 UTC 2023
|
Record UNII |
7RRQ8QZ38N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M8376
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | Merck Index | ||
|
1493000
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
100000079735
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
PAMOIC ACID
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
7RRQ8QZ38N
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
30188
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
SUB14746MIG
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
8546
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
50186
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
DTXSID9048984
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
130-85-8
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
204-998-0
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY | |||
|
C004368
Created by
admin on Thu Jul 06 11:00:08 UTC 2023 , Edited by admin on Thu Jul 06 11:00:08 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
NO peak value listed in USP-NF
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|